Ohm20, all the discussions I had heard mentioned Leronlimab had the potential to stop ARDS from occurring, the trial is setup to treat patients with respiratory complications not ARDS. Yes its possible the first two have ARDS already and critical so they are trying it, but not sure Leronlimab was intended to treat the virus in that late stage.

Bruce Patterson M.D., CEO of IncellDX and advisor to CytoDyn, added, “Leronlimab binds to the CCR5 receptor inhibiting the migration of macrophages and the release on inflammatory cytokines including TNF and IL-6. This release of cytokines is what is commonly referred to as the 'cytokine storm' and is believed to cause profound damage in the lungs in some patients. In addition, leronlimab can block Regulatory T cells (Tregs), which can inhibit the innate immune response against pathogens, into areas of inflammation. These combined mechanisms of action may reduce the morbidity and mortality in moderate to severe cases of COVID-19, preventing the acute respiratory distress syndrome associated with this highly destructive and potentially fatal disease.”